Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion ofcis-dichlorodiammine platinum(II)

Abstract

Platinum microquantities were determined in plasma of patients affected by lung carcinoma during treatment with radiotherapy (RT) and concurrent low-dose continuous infusion ofcis-dichlorodiammineplatinum(II) (CDDP). RT was given at 50 Gy in continuous course; CDDP was continuously infused at 4 mg/m2 daily for 100h/week for 5 weeks, and the infusions were separated by 68h of rest. The percentage of free drug versus total drug in plasma was about 3%. It did not vary with therapy duration and was not significantly different from that found in 5-day continuous infusions at much higher daily doses. Never-theless, maximal values of free Pt in plasma were very low and agreed with the low level of CDDP toxicity encountered on the present administration schedule.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bannister S, Sternson LA, Repta AJ, James GW (1977) Measurement of free-circulatingcis-dichlorodiammineplatinum(II) in plasma. Clin Chem 23: 2258–2262

  2. 2.

    Bedini AV, Tavecchio L, Milani F, Gramaglia A, Spreafico C, Marchiano A, Ravasi G (1993) Non-resectable stage III a-b Lung carinoma: a phase II study on continuous infusion of cisplatin and concurrent radiotherapy (plus adjuvant surgery). Lung Cancer 10: 73–84

  3. 3.

    Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, O'Leary GP Jr, Griffin H, Phaneuf MA, O'Rourke A, Calabresi P (1986) Cisplatin administered as continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep 70: 1215–1217

  4. 4.

    Curran WJ, Stafford PM (1990) Lack of apparent difference in outcome between clinically staged IIIa and IIIb non-small-cell lung cancer treated with radiation therapy. J Clin Oncol 8: 409–415

  5. 5.

    Dominici C, Alimonti A, Caroli S, Petrucci F, Castello MA (1986) Chemotherapeutic agent cisplatin monitoring in biological fluids by means of inductively coupled plasma emission spectrometry (ICP-AES). Clin Chim Acta 158: 207–215

  6. 6.

    Dominici C, Petrucci F, Caroli S, Alimonti A, Clerico A, Castello MA (1989) A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol 7: 100–107

  7. 7.

    Hazuka MB, Bunn PA Jr, Crowley J (1991) Maximum tolerated dose for low-dose continuous infusion cisplatin. Int J Radiat Oncol Biol Phys 21: 869–870

  8. 8.

    Johnson DH, Einhorn LH, Bartolucci A (1990) Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113: 33–38

  9. 9.

    Powell MJD (1964) An efficient method for finding the minimum of a function of several variables without calculating derivatives. Comput J 7: 155–162

  10. 10.

    Schaake-Koning C, Van den Bogaert W, Dalesio O, et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524–530

Download references

Author information

Correspondence to Franca Morazzoni.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Morazzoni, F., Canevali, C., Moschetti, I. et al. Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion ofcis-dichlorodiammine platinum(II). Cancer Chemother. Pharmacol. 35, 529–532 (1995). https://doi.org/10.1007/BF00686840

Download citation

Key words

  • CDDP
  • Continuous venous infusion
  • Lung carcinoma